Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC.

Ling PengKui XiaoJian CuiXiang-Hua YeYong-Chang ZhangLi MaoGiovanni SelvaggiJennifer YenJustin Stebbing

Published in: OncoTargets and therapy (2021)

This is the first report of ensartinib treatment after alectinib-induced hyperbilirubinemia which was successfully relieved by ALSS treatment and targeted drug cessation.

Keyphrases

high glucose
small cell lung cancer
diabetic rats
drug induced
advanced non small cell lung cancer
emergency department
combination therapy
drug delivery